View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 23, 2021

LumiraDx and CA Healthcare Acquisition revise merger agreement

On closing the deal, current LumiraDx stakeholders will retain the entirety of their present holdings in the company. 

LumiraDx and special purpose acquisition company (SPAC), CA Healthcare Acquisition (CAHC), have revised the transaction terms of their proposed merger to adjust the former’s pro forma valuation for the combined group from $5bn to $3bn.

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

The revision is based on several factors, including the latest market setting for publicly traded diagnostic firms, a general fall in the Covid-19 testing market and feedback from advisors and shareholders of CAHC.

The updated pro forma valuation excludes $115m raised by CAHC in its initial public offering.

Assuming no redemptions of current public stakeholders of CAHC, the merged company is expected to receive this sum in cash held in trust.

LumiraDx is a point of care diagnostics testing company with ten new tests awaiting approvals in the next two years on its platform, including Troponin, Flu/Covid and tuberculosis tests.

The company’s growth in implementing its platform, extending its testing menu and enlisting clients in key regions, along with the adjusted valuation, creates an attractive investment thesis for long-term stakeholder value, LumiraDx noted.

LumiraDx chairman and CEO Ron Zwanziger said: “We are growing our presence in the point of care testing market across cardiovascular disease, diabetes, coagulation disorders and infectious disease and have a strong pipeline and go-to-market strategy for driving growth over the coming years.

“Today’s announcement reflects our commitment to delivering significant upside potential and long-term value for both our current CAHC shareholders as well as future shareholders of LumiraDx .”

Subject to approval from CAHC and LumiraDx security holders and customary closing conditions, the business combination is anticipated to conclude in the coming months.

Present stakeholders of LumiraDx will retain the entirety of their current holdings in the company after the conclusion of the merger.

Cash from operations and the further capital from CAHC’s cash held in trust, following any redemptions, will offer growth capital to boost production and continue research and development works, as well as commercial and production expansion.

The boards of directors of LumiraDx and CAHC confirmed their recommendation of the transaction.

Earlier this month, the US Food and Drug Administration granted emergency use authorisation to LumiraDx ’s SARS-CoV-2 Ab test.

Related Companies

Free Report
img

What is driving M&A activity in the MedTech space?

The COVID-19 pandemic has left an indelible mark on the MedTech landscape. Changes in how healthcare is delivered, and new treatment modalities, are creating opportunities and challenges for both new and traditional players. As companies sought out opportunities during the pandemic-driven downturn, the number and value of mergers and acquisition deals in the MedTech space increased. Companies worked to reposition themselves in the newly aligned healthcare world, but with further economic turmoil expected: will these trends be repeated? And what tech areas should firms be looking to expand their capabilities into? GlobalData’s report, “Themes driving M&A activity in the Medical Devices Sector, Q1 2022,” draws upon GlobalData’s extensive MedTech deals databases, highlighting major trends and hot themes in M&A activity. This report will assist you in:
  • Understanding value and volume trends in M&A from Q1 2018 to Q1 2022
  • Understanding regional trends in M&A activity
  • Understanding which medical device sectors are leading M&A activity, and which are lagging
  • Understanding the leading tech trends in Q1 2022 M&A activity
  • Knowing the key deals that occurred during Q1 2022
Download the full report to understand what to expect and how to align your business for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network